6 results
To test the hypothesis that LY3314814, administered orally at doses of 20 and 50 mg daily for 78 weeks, will slow the decline of AD ascompared with placebo in patients with mild AD dementia.
The objective of this study is to evaluate the efficacy and safety of upadacitinib versus dupilumab for the treatment of adult subjects with moderate to severe atopic dermatitis who are candidates for systemic therapy.
The primary objective of the study is to evaluate the efficacy of REGN3500monotherapy compared with placebo treatment in adult patients withmoderate-to-severe atopic dermatitis (AD).The secondary objectives of the study are:* To evaluate the…
Objectives:Primary Objectives:1. To evaluate the efficacy of BAN2401 compared to placebo by establishing the ED90 (as defined in theprotocol) for BAN2401 on the derived Composite Clinical Score at 12 months of treatment in subjects withEarly…
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/…
The primary objectives of the study by study part are:Part A:To determine the treatment effect of dupilumab compared with placeboin adult and adolescent patients with EoE after 24 weeks of treatment as assessed by histological and clinical measures…